SCHEMBL14849673

SCHEMBL14849673

c1ccc(Oc2ccc(C3CCCOC3)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.44
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
CYP19A1 P11511 1/20 0.40
LMNA P02545 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
LTA4H P09960 1/20 0.39
TSHR P16473 1/20 0.39
PDE10A Q9Y233 2/20 0.38
PRKAB2 O43741 1/20 0.38
PRKAG1 P54619 1/20 0.38
PRKAA2 P54646 1/20 0.38
PRKAA1 Q13131 1/20 0.38
PRKAG3 Q9UGI9 1/20 0.38
PRKAG2 Q9UGJ0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14849768 0.84 SLC18A3 (0.42) TSHRPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL7477065 0.84 SLC18A3 (0.42) TSHRPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL23483033 0.81 PRKAB2 (0.45) KDM1ANPC1RAB9APRKAB2PRKAG1
SCHEMBL8710331 0.81 KDM1A (0.53) KDM1ALTA4HTSHRMMP3SMN1; SMN2
SCHEMBL26154062 0.81 KDM1A (0.53) KDM1ALTA4HTSHRKCNH2SCN3A
SCHEMBL9341092 0.80 DRD2 (0.43) KDM1AHPGDLMNAKMT2AMEN1
SCHEMBL27967916 0.79 SLC18A3 (0.42) TSHRSMN1; SMN2
SCHEMBL7702531 0.79 HAO1 (0.53) KDM1ATP53LMNAHTTLTA4H
SCHEMBL14849785 0.78 HTR1A (0.55) KDM1ANPC1TP53POLBHPGD
SCHEMBL3970721 0.77 KDM1A (0.57) KDM1ANPC1RAB9ALTA4HTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765751-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-01 US disclosed
US-20130089624-A1 Compounds Useful as Inhibitors of ATR Kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130089624-A1 Compounds Useful as Inhibitors of ATR Kinase ATR, CHEK1, PLK1 KDM1A 2426/4885NPC1 3026/4885TP53 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.